ACN vs LIXT · P/E 24, rev $17.60B vs $121.0M cap
Accenture plc (ACN) versus Lixte Biotechnology Holdings Inc (LIXT) — a side-by-side from cached financials, not a winner call.
Accenture plc (ACN) is a information technology services company listed on US.
Lixte Biotechnology Holdings Inc (LIXT) is a biotechnology company listed on NASDAQ.
Latest reported ACN revenue for 2025-08-31 was $17.60B. Net income was $1.41B. Revenue was down 0.7% from 2025-05-31 to 2025-08-31. ACN currently screens at market cap $186.16B and trailing P/E 23.8.
LIXT does not have a complete income-statement cache yet.
ACN currently screens at market cap $186.16B and trailing P/E 23.8. LIXT currently screens at market cap $121.0M.
Not investment advice. Open the ACN and LIXT stock pages for the full models.
Not investment advice.